skip to Main Content

Pembrolizumab Combo Extends Chemotherapy Benefit in Pancreatic Cancer

Pembrolizumab Combo Extends Chemotherapy Benefit in Pancreatic Cancer
Positive data from the phase IIa COMBAT clinical trial indicate that CXCR4 and PD-1 blockade with the combination of pembrolizumab (Keytruda) and BL-8040 (motixafortide) can improved upon the benefit of chemotherapy as treatment of pancreatic ductal adenocarcinoma (PDAC).

The COMBAT study (NCT02826486) is one of the first clinical trials to demonstrate a benefit for patients with metastatic pancreatic cancer with immunotherapy, according to the study authors. Read more . . . 


Back To Top